Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats

PPAR Research

Volumn , Issue , 2009, Pages

  Blasi, Eileen R ^a   Tiwari, Swasti ^b   Heyen, Jonathan ^a   Hemkens, Michelle ^a   McHarg, Aileen ^a   Ecelbarger, Carolyn M ^b  

^a PFIZER INC   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALDOSTERONE; GLUCOSE; HEMOGLOBIN; PD 0344168; PD 168; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ALDOSTERONE URINE LEVEL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CARDIOTOXICITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE COMPARISON; ECHOCARDIOGRAPHY; EDEMA; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE RELAXATION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HORMONE ACTION; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 68149125511     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2009/237865     Document Type: Article

References (57)

1. Barger P. M., Kelly D. P., PPAR signaling in the control of cardiac energy metabolism Trends in Cardiovascular Medicine 2000 10 6 238 245
2. Duan S. Z., Ivashchenko C. Y., Russell M. W., Milstone D. S., Mortensen R. M., Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor- both induce cardiac hypertrophy in mice Circulation Research 2005 97 4 372 379
3. Mehrabi M. R., Thalhammer T., Haslmayer P., The peroxisome proliferator-activated receptor gamma (PPAR ) is highly expressed in human heart ventricles Biomedicine Pharmacotherapy 2002 56 8 407 410
4. Newaz M., Blanton A., Fidelis P., Oyekan A., NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR) -mediated cardiovascular effects Mutation Research 2005 579 1-2 163 171
5. Komers R., Vrna A., Thiazolidinedionestools for the research of metabolic syndrome X Physiological Research 1998 47 4 215 225
6. Day C., Thiazolidinediones: a new class of antidiabetic drugs Diabetic Medicine 1999 16 3 179 192
7. Xu C., Wang L.-L., Liu H.-Y., Zhou X.-B., Cao T.-L., Li S., C333H, a novel PPAR / dual agonist, has beneficial effects on insulin resistance and lipid metabolism Acta Pharmacologica Sinica 2006 27 2 223 228
8. Kim H., Haluzik M., Asghar Z., Peroxisome proliferator-activated receptor- agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis Diabetes 2003 52 7 1770 1778
9. Hegarty B. D., Furler S. M., Oakes N. D., Kraegen E. W., Cooney G. J., Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivoa study using the novel PPAR / agonist tesaglitazar Endocrinology 2004 145 7 3158 3164
10. Martens F. M. A. C., Visseren F. L. J., Lemay J., de Koning E. J. P., Rabelink T. J., Metabolic and additional vascular effects of thiazolidinediones Drugs 2002 62 10 1463 1480
11. Chen Z., Ishibashi S., Perrey S., Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 3 372 377
12. Francis G. A., Annicotte J.-S., Auwerx J., PPAR agonists in the treatment of atherosclerosis Current Opinion in Pharmacology 2003 3 2 186 191
13. Nissen S. E., Wolski K., Topol E. J., Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus Journal of the American Medical Association 2005 294 20 2581 2586
14. Schiffrin E. L., Peroxisome proliferator-activated receptors and cardiovascular remodeling American Journal of Physiology 2005 288 3 H1037 H1043
15. Thiemermann C., Ligands of the peroxisome proliferator-activated receptor- and heart failure British Journal of Pharmacology 2004 142 6 1049 1051
16. Home P. D., Pocock S. J., Beck-Nielsen H., Rosiglitazone evaluated for cardiovascular outcomesan interim analysis The New England Journal of Medicine 2007 357 1 28 38
17. Hollenberg N. K., Considerations for management of fluid dynamic issues associated with thiazolidinediones The American Journal of Medicine 2003 115 8, supplement 1 111 115
18. Karalliedde J., Buckingham R. E., Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies Drug Safety 2007 30 9 741 753
19. Kaseta J. R., Skafar D. F., Ram J. L., Jacober S. J., Sowers J. R., Cardiovascular disease in the diabetic woman The Journal of Clinical Endocrinology Metabolism 1999 84 6 1835 1838
20. Barrett-Connor E., Giardina E.-G. V., Gitt A. K., Gudat U., Steinberg H. O., Tschoepe D., Women and heart disease: the role of diabetes and hyperglycemia Archives of Internal Medicine 2004 164 9 934 942 (Pubitemid 38581511)
21. Tiwari S., Blasi E. R., Heyen J., McHarg A., Ecelbarger C. M., Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats Pharmacological Research 2008 57 5 383 392
22. Houseknecht K. L., Cole B. M., Steele P. J., Peroxisome proliferator-activated receptor gamma (PPAR ) and its ligands: a review Domestic Animal Endocrinology 2002 22 1 1 23
23. Sotiropoulos K. B., Clermont A., Yasuda Y., Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPAR agonists effects on edema and weight gain The FASEB Journal 2006 20 8 1203 1205
24. Muranaka K., Yanagi Y., Tamaki Y., Effects of peroxisome proliferator-activated receptor and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model Investigative Ophthalmology and Visual Science 2006 47 10 4547 4552
25. Ito K., Shimada J., Kato D., Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor- ligand, on lung ischemia-reperfusion injury in rats European Journal of Cardio-Thoracic Surgery 2004 25 4 530 536
26. Idris I., Gray S., Donnelly R., Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability Diabetologia 2003 46 2 288 290
27. Guan Y., Hao C., Cha D. R., Thiazolidinediones expand body fluid volume through PPAR stimulation of ENaC-mediated renal salt absorption Nature Medicine 2005 11 8 861 866
28. Zhang H., Zhang A., Kohan D. E., Nelson R. D., Gonzalez F. J., Yang T., Collecting duct-specific deletion of peroxisome proliferator-activated receptor blocks thiazolidinedione-induced fluid retention Proceedings of the National Academy of Sciences of the United States of America 2005 102 26 9406 9411
29. Song J., Knepper M. A., Hu X., Verbalis J. G., Ecelbarger C. A., Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats The Journal of Pharmacology and Experimental Therapeutics 2004 308 2 426 433
30. Hong G., Lockhart A., Davis B., PPAR activation enhances cell surface ENaC via up-regulation of SGK1 in human collecting duct cells The FASEB Journal 2003 17 13 1966 1968
31. Nofziger C., Chen L., Shane M. A., Smith C. D., Brown K. K., Blazer-Yost B. L., PPAR agonists do not directly enhance basal or insulin-stimulated Na + transport via the epithelial Na + channel Pflgers Archiv European Journal of Physiology 2005 451 3 445 453
32. Nakamura Y., Ohya Y., Onaka U., Fujii K., Abe I., Fujishima M., Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig British Journal of Pharmacology 1998 123 4 675 682 (Pubitemid 128515017)
33. Eto K., Ohya Y., Nakamura Y., Abe I., Fujishima M., Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle European Journal of Pharmacology 2001 423 1 1 7
34. Panchapakesan U., Chen X.-M., Pollock C. A., Drug insight: thiazolidinediones and diabetic nephropathyrelevance to renoprotection Nature Clinical Practice. Nephrology 2005 1 1 33 43
35. Sarafidis P. A., Bakris G. L., Protection of the kidney by thiazolidinediones: an assessment from bench to bedside Kidney International 2006 70 7 1223 1233
36. Isshiki K., Haneda M., Koya D., Maeda S., Sugimoto T., Kikkawa R., Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats Diabetes 2000 49 6 1022 1032
37. Ueta M., Wakisaka M., Ago T., PPAR ligands attenuate mesangial contractile dysfunction in high glucose Kidney International 2004 65 3 961 971
38. Chana R. S., Brunskill N. J., Thiazolidinediones inhibit albumin uptake by proximal tubular cells through a mechanism independent of peroxisome proliferator activated receptor gamma American Journal of Nephrology 2006 26 1 67 74
39. Haneda M., Koya D., Kikkawa R., Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway American Journal of Kidney Diseases 2001 38 4, supplement 1 S178 S181
40. Mandal A. K., Hiebert L. M., Renal protection in diabetes: is it affected by glucose control or inhibition of the renin-angiotensin pathway? Clinical Nephrology 2008 69 3 169 178
41. Fioretto P., Bruseghin M., Berto I., Gallina P., Manzato E., Mussap M., Renal protection in diabetes: role of glycemic control Journal of the American Society of Nephrology 2006 17 4, supplement 2 S86 S89
42. Hatt P. Y., Rakusan K., Gastineau P., Laplace M., Morphometry and ultrastructure of heart hypertrophy induced by chronic volume overload (aorto-caval fistula in the rat) Journal of Molecular and Cellular Cardiology 1979 11 10 989 998
43. Lecarpentier Y., Martin J. L., Gastineau P., Hatt P. Y., Load dependence of mammalian heart relaxation during cardiac hypertrophy and heart failure American Journal of Physiology 1982 242 5 H855 H861
44. Arakawa K., Ishihara T., Aoto M., Inamasu M., Kitamura K., Saito A., An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats Clinical and Experimental Pharmacology and Physiology 2004 31 1-2 8 13
45. Sena S., Rasmussen I. R., Wende A. R., Cardiac hypertrophy caused by peroxisome proliferator-activated receptor- agonist treatment occurs independently of changes in myocardial insulin signaling Endocrinology 2007 148 12 6047 6053
46. Anavekar N. S., Solomon S. D., Angiotensin II receptor blockade and ventricular remodelling Journal of the Renin-Angiotensin-Aldosterone System 2005 6 1 43 48
47. Westendorp B., Schoemaker R. G., Buikema H., Boomsma F., van Veldhuisen D. J., van Gilst W. H., Progressive left ventricular hypertrophy after withdrawal of long-term ACE inhibition following experimental myocardial infarction European Journal of Heart Failure 2006 8 2 122 130
48. Wilke A., Funck R., Rupp H., Brilla C. G., Effect of the renin-angiotensin-aldosterone system on the cardiac interstium in heart failure Basic Research in Cardiology 1996 91 2, supplement 1 79 84
49. Son N.-H., Park T.-S., Yamashita H., Cardiomyocyte expression of PPAR leads to cardiac dysfunction in mice Journal of Clinical Investigation 2007 117 10 2791 2801
50. Kim S. K., Zhao Z. S., Lee Y. J., Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR- or- agonists in a type 2 diabetic animal model Diabetes/Metabolism Research and Reviews 2003 19 6 487 493
51. Rodriguez W. E., Joshua I. G., Falcone J. C., Tyagi S. C., Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced type 2 diabetes mellitus American Journal of Physiology 2006 291 1 H81 H87
52. Nemoto S., Razeghi P., Ishiyama M., De Freitas G., Taegtmeyer H., Carabello B. A., PPAR- agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation American Journal of Physiology 2005 288 1 H77 H82
53. Pischon T., Girman C. J., Hotamisligil G. S., Rifai N., Hu F. B., Rimm E. B., Plasma adiponectin levels and risk of myocardial infarction in men Journal of the American Medical Association 2004 291 14 1730 1737
54. Hong S. J., Park C. G., Seo H. S., Oh D. J., Ro Y. M., Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index Blood Pressure 2004 13 4 236 242
55. Menon V., Li L., Wang X., Adiponectin and mortality in patients with chronic kidney disease Journal of the American Society of Nephrology 2006 17 9 2599 2606 (Pubitemid 44300977)
56. Kistorp C., Faber J., Galatius S., Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure Circulation 2005 112 12 1756 1762
57. Komaba H., Igaki N., Goto S., Adiponectin is associated with brain natriuretic peptide and left ventricular hypertrophy in hemodialysis patients with type 2 diabetes mellitus Nephron. Clinical Practice 2007 107 3 c103 c108